Disposition of [¹⁴C₂]-Labeled LY3039478 Following Oral Administration in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 12 Jan 2017
At a glance
- Drugs Crenigacestat (Primary)
- Indications Lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours
- Focus Pharmacokinetics
- Sponsors Eli Lilly
- 06 Jan 2017 Status changed from recruiting to completed.
- 05 Oct 2016 Status changed from not yet recruiting to recruiting.
- 30 Sep 2016 New trial record